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  We studied the role of chemotherapy in cancer cachexia, which is well known to lower QOL 
as well as responsiveness to chemotherapy.  In BALB/c mice we used two clones derived from 
the murine colon 26 adenocarcinoma cell line, clone 5, a non-cachexigenic tumor and clone 20, 
a cachexigenic tumor, in which IL-6 mRNA was selectively detected.  While maximum 
tolerated dose (MTD) of CPM and CPT-11 showed significantly smaller tumor weight and 
higher survival than 1/2 MTD in both drug groups with clone 5, the results were reversed with 
clone 20 (Fig 1). The tumor weights with MTD of CPM or CPT-11 in combination with 
anti-IL-6 antibody treatment, which decreases serum IL-6 level and improves cachexia status, 
were significantly smaller than those in the MTD treatment-alone group with clone 20, but not 
with clone 5 (Fig 2).    
  From these results, we suggest that lower dose chemotherapy or cachexia-controlled 
chemotherapy such as some chemotherapeutic agents with neutralizing cachexia-related 
cytokine effects, elicits superior antitumor effects in cachectic individuals than conventional 




































































Fig 1. Survival curves of CPT-11 therapy   Fig. 2. The effect of anti-IL-6 antibody 
 
